Business Wire

Talkdesk Raises $143 Million in Series C Funding

23.7.2020 17:00:00 EEST | Business Wire | Press release

Share

Talkdesk®, Inc., the cloud contact center for innovative enterprises, today announced $143 million in Series C funding from a combination of new and existing investors. The amount raised, and the company’s valuation of more than $3 billion, reflects both investor confidence in Talkdesk’s business and the strategic role that superior customer experience plays among top global brands.

New investors participating in this latest round include Franklin Templeton, Willoughby Capital, Skip Capital, Lead Edge Capital and Top Tier Capital Partners, along with existing partners Viking Global Investors and Threshold Ventures. In total, Talkdesk has raised $268 million over its funding rounds, strengthening its leadership position in the Contact Center as a Service (CCaaS) marketplace and solidifying the role of customer experience as a strategic differentiator for enterprises.

This latest investment follows a year of continued global growth, product development and market leadership for Talkdesk. Over the past 12 months Talkdesk has introduced more than 600 product innovations to the market including Talkdesk 20-in-20, an ambitious release program to lead the contact center industry by starting 2020 with 20 product introductions in the first 20 weeks. Talkdesk’s culture of innovation led to 200 patent submissions in 100 days and continues to push customer service ahead with industry advancements like CXTalent and multiple awards.

The new funding will allow Talkdesk to capitalize on its current momentum and continue its global growth. The company plans to increase research and development spending and to invest in go-to-market, sales, marketing and channel development as Talkdesk continues to expand up-market.

Helping Brands Differentiate Through Customer Service During COVID-19

While companies have historically made significant investments in their contact centers as a means of differentiation through customer support, COVID-19 has served as a catalyst for accelerated investment in cloud-based solutions. Many consumer-facing brands have effectively lost their primary retail channel, making the need to provide world-class support a strategic imperative. As many enterprises move operations to a completely remote setting for the first time, Talkdesk’s cloud-native solutions ensure that agents can deliver an exceptional customer experience regardless of their location.

“The importance of providing an unparalleled customer experience has never been greater and this latest funding is a reflection of the criticality of this aspect as brands look for avenues for growth in our current environment,” said Tiago Paiva, chief executive officer, Talkdesk. “We are incredibly appreciative of the support and confidence of our investors, customers and partners who continue to endorse our vision of providing the industry’s most innovative and flexible solutions for the modern contact center. Lastly, I want to share my immense gratitude for the dedication and expertise of our employees who enable us to deliver for our customers, even during the most challenging times.”

"The global pandemic has fueled the importance of customer experience for business continuity. Talkdesk provides an innovative CX platform and solutions to help every organization provide the best possible and amazing customer experience,” said Mark Smith, chief executive officer and chief research officer, Ventana Research. “Our recognition of Talkdesk to receive the Ventana Research Digital Innovation Award in CX for 2020 is yet another example of the investment in innovation. The growth and funding is testament to the confidence and trust in the brand by customers and partners who have committed to Talkdesk."

The Talkdesk team consists of some of the world’s top authorities in the area of CCaaS and customer experience. The organization is a strategic and reliable provider to its customer base of more than 1,800 innovative customers in 75 countries including IBM, Acxiom, 2U, Trivago and Peloton.

Supporting Investor Quotes:

“We are excited to join Talkdesk in its journey to reimagine a critical element of business to consumer communications infrastructure, as businesses seek to enhance their relationships with customers with next generation digital engagement tools. Talkdesk’s market potential is large, and its business model is promising,” said Jonathan Curtis, vice president, research analyst and portfolio manager with Franklin Templeton’s Franklin Equity Group.

“We have been incredibly impressed by Talkdesk and the remarkable growth and scale the company has achieved over the last few years,” said Morgan Rutman, president, Willoughby Capital. “The company’s solutions are mission-critical across a range of industries during these challenging times. We are excited to support Tiago and the team through the next stage of the company’s evolution.”

"With a best-in-class product, Talkdesk’s rapid growth in the enterprise contact center segment is extremely impressive,” said Kim Jackson, founder, Skip Capital. “We are excited about accelerating cloud adoption, and as businesses of all sizes look for tools to help with a shift to remote work, Talkdesk’s product suite is highly compelling. We are thrilled to join the Talkdesk team on their journey."

"Talkdesk is a step above the outdated, legacy contact center systems and has quickly established itself as the vendor-of-choice. We're excited to partner with the company as its suite of products reaches an even greater scale," said Mitchell Green, managing partner, Lead Edge Capital. “Talkdesk is experiencing explosive adoption of its technology, and it is no surprise given the pain points its solving for companies, large and small.”

“Talkdesk is leveraging software and innovation to disrupt the traditional call center,” said Garth Timoll, managing director, Top Tier Capital Partners. “The company has emerged as a clear leader in the CCaaS sector and Top Tier Capital Partners is excited to support Talkdesk’s continued growth.”

"Threshold Ventures partners with exceptional entrepreneurs who have a vision for transformative, market-changing solutions. Tiago and the Talkdesk team are innovatively pushing CCaaS applications to a new level,” said Josh Stein, partner, Threshold Ventures. “Since leading their Series A financing, we’ve had a front row seat to watch Talkdesk emerge as an undisputed leader in the large CCaaS market."

Additional Resources:

Tweet this: .@Talkdesk raises $143M in Series C funding. Valuation of $3B+ highlights the strategic role of superior customer experience among top global brands. https://bit.ly/3eUo5me

Social Networks:

About Talkdesk

Talkdesk® is the cloud contact center for the customer-obsessed. Combining enterprise performance with consumer simplicity, Talkdesk easily adapts to the evolving needs of support and sales teams and their end-customers, resulting in higher customer satisfaction, productivity and cost savings. Over 1,800 innovative companies around the world, including IBM, Acxiom, 2U, Trivago and Peloton, rely on Talkdesk to make customer experience their competitive advantage. Learn more and request a demo at www.talkdesk.com.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gavin Gustafson
gavin.gustafson@talkdesk.com
(801) 560-0073

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye